Evidence map›Paper›PMID 38132140›Full record

ArticleCells2023

Integrated Analysis of lncRNA-miRNA-mRNA Regulatory Network in Rapamycin-Induced Cardioprotection against Ischemia/Reperfusion Injury in Diabetic Rabbits.

Arun Samidurai, Amy L Olex, Ramzi Ockaili, Donatas Kraskauskas, Sean K Roh, Rakesh C Kukreja, Anindita Das

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Epigenetic regulation in a high-sugar environment (Review).International journal of molecular medicine · 2026
    Review
  2. Role of the lncRNA MALAT1/miR-1 Pathway in Mouse Myocardial Ischemia-Reperfusion Injury.Endocrine, metabolic & immune disorders drug targets · 2026
    Article
  3. LncRNA MEG3 RegulatesMicroorganisms · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Arun SamiduraiDivision of Cardiology, Pauley Heart Center, Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.ORCID 0000-0002-5360-2553
Amy L OlexWright Center for Clinical and Translational Research, Virginia Commonwealth University, Richmond, VA 23298, USA.ORCID 0000-0001-8064-521X
Ramzi OckailiDivision of Cardiology, Pauley Heart Center, Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
Donatas KraskauskasDivision of Cardiology, Pauley Heart Center, Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
Sean K RohDivision of Cardiology, Pauley Heart Center, Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
Rakesh C KukrejaDivision of Cardiology, Pauley Heart Center, Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
Anindita DasDivision of Cardiology, Pauley Heart Center, Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.ORCID 0000-0003-4422-7277
Virginia Commonwealth University · US

Funding

Amelioration of Doxorubicin Induced Muscle Dysfunction with Embryonic Stem Cell-Derived ExosomesR01CA221813 · NCI · UNIVERSITY OF CENTRAL FLORIDA · PI KUKREJA, RAKESH C, SINGLA, DINENDER KUMAR · 2018 to 2024
$3.1M
Novel Strategy of PDE5-mTOR Inhibition in Attenuation of Cancer Drug CardiotoxicityR01HL158951 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DAS, ANINDITA, KUKREJA, RAKESH C · 2022 to 2025
$2.1M
Cardioprotection with mTOR InhibitionR01HL134366 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DAS, ANINDITA, KUKREJA, RAKESH C · 2016 to 2019
$2.1M
NCI NIH HHS R01 CA221813NHLBI NIH HHS R01 HL134366NHLBI NIH HHS R01 HL158951NIH HHS RO1HL134366NIH HHS RO1HL158951
6 · The paper itself

Abstract

The inhibition of mammalian target of rapamycin (mTOR) with rapamycin (RAPA) provides protection against myocardial ischemia/reperfusion (I/R) injury in diabetes. Since interactions between transcripts, including long non-coding RNA (lncRNA), microRNA(miRNA) and mRNA, regulate the pathophysiology of disease, we performed unbiased miRarray profiling in the heart of diabetic rabbits following I/R injury with/without RAPA treatment to identify differentially expressed (DE) miRNAs and their predicted targets of lncRNAs/mRNAs. Results showed that among the total of 806 unique miRNAs targets, 194 miRNAs were DE after I/R in diabetic rabbits. Specifically, eight miRNAs, including miR-199a-5p, miR-154-5p, miR-543-3p, miR-379-3p, miR-379-5p, miR-299-5p, miR-140-3p, and miR-497-5p, were upregulated and 10 miRNAs, including miR-1-3p, miR-1b, miR-29b-3p, miR-29c-3p, miR-30e-3p, miR-133c, miR-196c-3p, miR-322-5p, miR-499-5p, and miR-672-5p, were significantly downregulated after I/R injury. Interestingly, RAPA treatment significantly reversed these changes in miRNAs. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis indicated the participation of miRNAs in the regulation of several signaling pathways related to I/R injury, including MAPK signaling and apoptosis. Furthermore, in diabetic hearts, the expression of lncRNAs, HOTAIR, and GAS5 were induced after I/R injury, but RAPA suppressed these lncRNAs. In contrast, MALAT1 was significantly reduced following I/R injury, with the increased expression of miR-199a-5p and suppression of its target, the anti-apoptotic protein Bcl-2. RAPA recovered MALAT1 expression with its sponging effect on miR-199-5p and restoration of Bcl-2 expression. The identification of novel targets from the transcriptome analysis in RAPA-treated diabetic hearts could potentially lead to the development of new therapeutic strategies for diabetic patients with myocardial infarction.

Indexed as

Diabetes MellitusLagomorphaMicroRNAsMyocardial Reperfusion InjuryRNA, Long NoncodingAnimalsHumansIschemiaProto-Oncogene Proteins c-bcl-2RabbitsRNA, MessengerMicroRNAsMirn140 microRNA, humanMIRN154 microRNA, humanMIRN299 microRNA, humanMIRN497 microRNA, humanMIRN543 microRNA, humanProto-Oncogene Proteins c-bcl-2RNA, Long NoncodingRNA, Messengerapoptosisdiabetesischemia/reperfusion injurylong non-coding RNAsMALAT1microRNAsmRNAsmTORrapamycin

Identifiers

PMID38132140
PMCPMC10742118
OpenAlexW4389617625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.